Scholarlink

<p>Extracellular high mobility group box 1 (HMGB1) serves as a key damage-associated molecular pattern that drives the pathological process of inflammatory liver injury; however, its role in liver fibrosis and the underlying mechanisms need to be elucidated. To investigate the proinflammatory and profibrotic roles of extracellular HMGB1, we used an adenovirus-mediated system to measure HMGB1 secretion in mice. We subsequently constructed two recombinant proteins, PfTrx-HMGB1<sup>17</sup>(95 − 111) and HBcΔ-HMGB1<sup>34</sup>(150 − 183), targeting the interactions of HMGB1 with its receptors, namely, toll-like receptor 4 (TLR4) and receptor for advanced glycation end products (RAGE), respectively. Mice were immunized with the two recombinant proteins to assess neutralizing antibody induction and the protective effects of the HMGB1 vaccines against carbon tetrachloride (CCl<sub>4</sub>)-induced liver fibrosis. Our results revealed the nucleocytoplasmic translocation of HMGB1 in the livers of both humans and mice with fibrosis. Extracellular HMGB1 induced liver inflammation and fibrogenesis in mice. Immunization with the two HMGB1 vaccines resulted in the production of high levels of anti-HMGB1 neutralizing antibodies, which inhibited the activation of hepatic stellate cells (LX-2) and the production of proinflammatory and profibrotic factors in RAW 264.7 cells. Furthermore, vaccination with these compounds significantly protected against CCl<sub>4</sub>-induced liver injury, inflammation, and fibrosis in mice. These findings demonstrate that extracellular HMGB1, by binding to TLR4 or RAGE, is pivotal in driving liver inflammation and fibrosis. Vaccination against HMGB1 through disruption of interaction with TLR4 or RAGE represents a promising therapeutic strategy for hepatic fibrosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Vaccination Against HMGB1 Protects Mice from CCl4-Induced Liver Injury, Inflammation, and Fibrosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月1日

查看全文
  • Qian Li,
  • Hanchao Li,
  • Yongwei Huo,
  • Hong Tian,
  • Li Zhu,
  • Xiaoyan Zheng,
  • Wengang Sun,
  • Xueting Zhang,
  • Zhiming Hao

摘要

Extracellular high mobility group box 1 (HMGB1) serves as a key damage-associated molecular pattern that drives the pathological process of inflammatory liver injury; however, its role in liver fibrosis and the underlying mechanisms need to be elucidated. To investigate the proinflammatory and profibrotic roles of extracellular HMGB1, we used an adenovirus-mediated system to measure HMGB1 secretion in mice. We subsequently constructed two recombinant proteins, PfTrx-HMGB117(95 − 111) and HBcΔ-HMGB134(150 − 183), targeting the interactions of HMGB1 with its receptors, namely, toll-like receptor 4 (TLR4) and receptor for advanced glycation end products (RAGE), respectively. Mice were immunized with the two recombinant proteins to assess neutralizing antibody induction and the protective effects of the HMGB1 vaccines against carbon tetrachloride (CCl4)-induced liver fibrosis. Our results revealed the nucleocytoplasmic translocation of HMGB1 in the livers of both humans and mice with fibrosis. Extracellular HMGB1 induced liver inflammation and fibrogenesis in mice. Immunization with the two HMGB1 vaccines resulted in the production of high levels of anti-HMGB1 neutralizing antibodies, which inhibited the activation of hepatic stellate cells (LX-2) and the production of proinflammatory and profibrotic factors in RAW 264.7 cells. Furthermore, vaccination with these compounds significantly protected against CCl4-induced liver injury, inflammation, and fibrosis in mice. These findings demonstrate that extracellular HMGB1, by binding to TLR4 or RAGE, is pivotal in driving liver inflammation and fibrosis. Vaccination against HMGB1 through disruption of interaction with TLR4 or RAGE represents a promising therapeutic strategy for hepatic fibrosis.